Plain-English translation of NCT06750731 on ClinicalTrials.gov ↗ ·
This trial is testing vedolizumab, a medication that helps control inflammatory bowel disease, by following patients over 22 weeks to see how well they stick to their treatment plan and how much their symptoms improve. You'll use a smartphone app to log your medication use and report your symptoms weekly at first, then monthly. The study wants to understand whether the medication works well in real-world conditions when patients use a remote monitoring app to help them stay on track.
Many patients with inflammatory bowel disease struggle to take their medications as prescribed, which can affect how well the treatment works. This study is trying to figure out if using a smartphone app to monitor and encourage medication adherence can help patients do better with their disease control.
You likely qualify if…
You likely don't qualify if…
Over 22 weeks, you'll take vedolizumab as prescribed and use a web-based app called Tappt to log when you take your doses. You'll also answer a quick two-question symptom check weekly for the first 6 weeks, then once a month through week 22. You'll visit the clinic or complete online forms at weeks 0, 2, 6, 14, and 22 to share information about your medication use, symptoms, quality of life, and overall health.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States